Skip to main content

Table 5 Optic nerve-based measures in patients and controls

From: The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

  PATIENTS CONTROLS  
  Clinically Affected
(mean, SD)
Clinically Unaffected
(mean, SD)
(mean, SD) p*
Number of optic nerves (n) 14 6 16 -
RNFL average thickness (microns) 72.4 (12.9) 85.5 (10.2) 101.6 (12.1) 0.0093
Macular volume (mm 3 ) 6.1 (0.5) 6.6 (0.3) 6.9 (0.4) 0.1211
Optic nerve area (mm 2 ) 8.1 (1.3) 8.9 (1.1) 10.3 (0.8) 0.0123
Optic nerve MTR (pu) 28.4 (2.9) 31.3 (2.3) 32.9 (3.4) 0.2700
Optic nerve DTI Mean Diffusivity (×10 -3 mm 2 /s) 1.17 (0.29) 1.25 (0.26) 0.97 (0.13) 0.0145
Optic nerve DTI Fractional Anisotropy (×10 3 ) 298.2 (91.2) 353.3 (88.6) 530.6 (99.7) 0.0004
Optic nerve DTI Radial Diffusivity (×10 -3 mm 2 /s) 0.99 (0.26) 1.03 (0.24) 0.67 (0.13) 0.0007
Optic nerve DTI Axial Diffusivity (×10 -3 mm 2 /s) 1.53 (0.42) 1.70 (0.35) 1.58 (0.23) 0.4809
  1. RNFL = Retinal Nerve Fibre Layer; VER = Visual Evoked Response; DTI = Diffusion Tensor Imaging. * Significance test for control vs. patient by 2-way ANOVA controlling for optic nerve status in patient group (clinically affected/unaffected)